Neuraxis, INC
NRXSNYSEHealthcare · Electromedical & Electrotherapeutic Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | $3.6M | $2.7M | $2.5M | $2.7M |
| Operating income | −$7.8M | −$7.2M | −$6.7M | −$3.4M |
| Net income | −$7.8M | −$8.2M | −$14.6M | −$4.8M |
| Total assets | $6.4M | $4.8M | $509,498 | $1.5M |
| Total liabilities | $3.0M | $2.7M | $1.9M | $7.1M |
| Equity | $3.4M | $2.1M | −$1.4M | −$5.6M |
| EPS (diluted) | $-0.95 | $-1.22 | $-4.50 | $-2.77 |
| Shares out. | 7.2M | 6.6M | 6.5M | 2.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −219.4%
- Net margin
- −218.5%
- Return on equity
- −229.5%
- Return on assets
- −121.8%
- Return on capital (ROCE)
- −216.8%
- Liabilities / assets
- 46.9%
- Debt / equity
- 0.88×
- Book value / share
- $0.47
- Revenue growth (YoY)
- 32.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -36.90distress
- Accruals / assets
- −21.4%clean
- Beneish M-Score
- -3.44normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2024
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Bigger Capital Fund L PPassive (13G)May 1, 2026
- Hannasch BrianPassive (13G)Jul 2, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Aharon GilDirector | Apr 28, 2026 | Grant | 12,304 | — |
| Henrichs Timothy RobertOfficer — Chief Financial Officer | Apr 1, 2026 | Buy | 7,593 | $1.96 |
| Carrico Thomas JoesephOfficer — CRO, CCO, CPO | Apr 1, 2026 | Buy | 667 | $1.96 |
| Carrico Brian AllenOfficer — Chief Executive Officer | Apr 1, 2026 | Buy | 8,060 | $1.96 |
| Watkins Bradley MitchellDirector | Jan 22, 2026 | Grant | 21,598 | $4.63 |
| Keyser Jane ElizabethDirector | Jan 22, 2026 | Grant | 21,598 | $4.63 |
| Hannasch Brian10% owner | Feb 11, 2026 | Buy | 40,000 | $4.65 |
| Aharon GilDirector | Jan 22, 2026 | Grant | 21,598 | $4.63 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 402,893 | 1.8 | +2.3% |
| Apr 30, 2026 | 393,690 | 2.0 | +49.4% |
| Apr 15, 2026 | 263,600 | 2.2 | +45.3% |
| Mar 31, 2026 | 181,362 | 1.0 | +18.1% |
| Mar 13, 2026 | 153,554 | 1.0 | +20.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventApr 22, 2026
- Results of operationsApr 21, 2026
- Other material eventOct 24, 2025
- Results of operationsOct 23, 2025
- Entered a material agreementSep 2, 2025
- Entered a material agreement · Terminated a material agreement · Director / officer changeJul 3, 2025
- Shareholder voteJun 4, 2025
- Regulation FD disclosureMay 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.